⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses

Official Title: PEG-asparaginase During Two Treatment Courses in the Treatment of Childhood Acute Lymphoblastic Leukemia

Study ID: NCT00192673

Interventions

PEG-asparaginase

Study Description

Brief Summary: The purpose of this study is 1. to determine the correct dose for intramuscular administration 2. to compare the frequency of antibody formation after intramuscular administration of native E.coli asparaginase and PEG-asparaginase during two treatment courses in the treatment of childhood lymphoblastic leukemia

Detailed Description: Asparaginase is used in the treatment of childhood lymphoblastic leukemia. Approximately 1/3 of the patients develops blocking antibodies against native E.coli asparaginase during the second exposure, so that they do not benefit from treatment and thus may have a worse prognosis. PEG-asparaginase is less immunogenic so that fewer patients may develop antibodies during the second exposure. There is no published study about the antibody formation after treatment of children with PEG-asparaginase during two treatment courses. The first part of the study is a description of the pharmacokinetics of PEG-asparaginase after intramuscular administration in order to determine the correct dose. The second part of the study is a comparison of antibody formation during two treatment courses after intramuscular administration og native E.coli asparaginase and PEG-asparaginase. Other side effects than antibodies will be registered during treatment with PEG-asparaginase. Finally comparison of the 5-year EFS between the groups (native E.coli asparaginase and PEG-asparaginase as well as patients who have and have not developed antibodies) will be evaluated.

Eligibility

Minimum Age: 1 Year

Eligible Ages: CHILD

Sex: ALL

Healthy Volunteers: No

Locations

Department of Pediatrics, Skejby Hospital, Aarhus, Aarhus N, Denmark

Contact Details

Name: Henrik Schrøder, M.D. PhD

Affiliation: Department of Pediatrics, Skejby Hospital, Denmark and member of the Scientific Commmittee in NOPHO

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: